Immunotherapy drugs known as immune checkpoint inhibitors have improved long-term cancer survival rates by allowing a person’s immune system to attack tumor cells. But there has been concern about their role in inflammatory and autoimmune disorders, known as immune-related adverse events, that can include hypothyroidism, colitis, and diabetes.
